Reviews in Urology Volume 24, Issue 3 2025Correction

Corrected disclosure informationRev Urol. 2025;24(3):e21.In the article titled “Anemia Management During PARP Inhibitor Therapy for Metastatic Castration-Resistant Prostate Cancer,” published June 23, 2025, in Reviews in Urology,¹ the conflict of interest disclosures and funding/support information were corrected. This article was corrected online and is available at https://reviewsinurology.com/issues/vol/24/no/2/anemia-management-during-parp-inhibitor-therapy-for-metastatic-castration-resistant-prostate-cancer.References

Dorff T, Hamilton J, Hafron JM, Lowentritt B. Anemia management during PARP inhibitor therapy for metastatic castration-resistant prostate cancer. Rev Urol. 2025;24(2):e41-e56.

CoverPLUVICTO®PLUVICTO 2Leadership & Editorial StaffERLEADACall For ManuscriptsContentslsoPSALetter From the President of LUGPABladder & Kidney Cancer AcademyLUGPA NewsCorrection2025 Annual MeetingProstate Cancer (Systematic Review)XofigoLUGPA 2026Prostate Cancer (Literature Review)Prostate Cancer (Clinical Trial Review)Bladder Cancer (Trial Review)Cardinal HealthBladder Cancer (Narrative Review)ZUSDURIBusiness of UrologyCoding CornerPfizerPfizer 2LUGPA MembershipCase of the QuarterCardinal Health: Theranostics WeekSpecialty NetworksCall For Manuscripts 2Opt-in cmePfizer 3